Every 4 years, leishmaniasis experts gather together from around the world. During World Leish 4, DNDi held 2 symposia on “partnering along the path to deliver better treatments”.
Clinical Symposium
“Improved Treatments for Visceral Leishmaniasis – Status of Ongoing Studies, and Challenges & Opportunities Ahead”
Early-Stage R&D Symposium
“Challenges for and Potential in the Early-Stage R&D Pipeline to Develop New Antileishmanial Drugs”
Programme
If you would like to download the full Programme, please click here.
Presentations
Clinical Symposium
1 Partnering along the path to deliver better treatments for visceral leishmaniasis
by Dr. Monique Wasunna
2 New treatments for visceral leishmaniasis in Africa – The story so far
by Prof Eltahir Khalil on behalf of Dr. Ahmed Mudawi Musa
3 Safety and Effectiveness of Liposomal Amphotericin B (AmBisome®) treatment for Visceral Leishmaniasis (VL) under routine programme conditions in Vaishali, Bihar, India.
by Dr. Nines Lima
4 Combination therapy for visceral leishmaniasis: Why, what, where ?
by Johan vn Grievsen and Marleen Boelaert
5 DNDi’s R&D strategy to improve treatment for VL: a needs-driven approach
by Dr. Manica Balasegaram
Early-Stage R&D Symposium
1 Current and Emerging Approaches in Antileishmanial Reasearch
by Denis Martin
2 “High Content and High Throughput Screening appliad to drug discovery for parasitic diseases”
by Dr. Lucio Freitas-Junior
3 Experimental models for lead optimisation of novel antileishmanial agents
by Sunil Puri
4 Substituted Quinolines as Leishmanicidal Drugs
by Alain Fournet
5 Visceral Leishmaniasias (VL) – Optimization of 2- Substituted Quinolines
by Vadiraj Gopinath
6 Variation of the parasite causing visceral leishmaniasis in East Africa
by Prof. Asrat Hailu
